How to buy Supernus Pharmaceuticals stock

Supernus Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Supernus Pharmaceuticals shares (SUPN) are listed on the NASDAQ and all prices are listed in US Dollars. Supernus Pharmaceuticals employs 563 staff and has a trailing 12-month revenue of around 0.00.

Supernus Pharmaceuticals share price

Use our graph to track the performance of SUPN stocks over time.

Supernus Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$17.20 - $32.31
50-day moving average	$27.69
200-day moving average	$25.30
Wall St. target price	$34.50
PE ratio	13.322
Dividend yield	N/A (0%)
Earnings per share (TTM)	$2.36

Buy Supernus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Supernus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Supernus Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Supernus Pharmaceuticals under- or over-valued?

Valuing Supernus Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Supernus Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Supernus Pharmaceuticals's P/E ratio

Supernus Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Supernus Pharmaceuticals shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Supernus Pharmaceuticals's PEG ratio

Supernus Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.47. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Supernus Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Supernus Pharmaceuticals's EBITDA

Supernus Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $206.2 million.

The EBITDA is a measure of a Supernus Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Supernus Pharmaceuticals financials

Revenue TTM	$520.4 million
Operating margin TTM	36.15%
Gross profit TTM	$467.9 million
Return on assets TTM	8.83%
Return on equity TTM	18.94%
Profit margin	24.4%
Book value	$14.09
Market capitalisation	$1.7 billion

TTM: trailing 12 months

Shorting Supernus Pharmaceuticals shares

There are currently 7.3 million Supernus Pharmaceuticals shares held short by investors – that's known as Supernus Pharmaceuticals's "short interest". This figure is 1.8% down from 7.5 million last month.

There are a few different ways that this level of interest in shorting Supernus Pharmaceuticals shares can be evaluated.

Supernus Pharmaceuticals's "short interest ratio" (SIR)

Supernus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Supernus Pharmaceuticals shares currently shorted divided by the average quantity of Supernus Pharmaceuticals shares traded daily (recently around 588487.24939856). Supernus Pharmaceuticals's SIR currently stands at 12.47. In other words for every 100,000 Supernus Pharmaceuticals shares traded daily on the market, roughly 12470 shares are currently held short.

However Supernus Pharmaceuticals's short interest can also be evaluated against the total number of Supernus Pharmaceuticals shares, or, against the total number of tradable Supernus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Supernus Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Supernus Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0.2068% of the tradable shares (for every 100,000 tradable Supernus Pharmaceuticals shares, roughly 207 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Supernus Pharmaceuticals.

Find out more about how you can short Supernus Pharmaceuticals stock.

Supernus Pharmaceuticals share dividends

We're not expecting Supernus Pharmaceuticals to pay a dividend over the next 12 months.

Supernus Pharmaceuticals share price volatility

Over the last 12 months, Supernus Pharmaceuticals's shares have ranged in value from as little as $17.2 up to $32.31. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Supernus Pharmaceuticals's is 1.2041. This would suggest that Supernus Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Supernus Pharmaceuticals overview

Supernus Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc.

Frequently asked questions

• What percentage of Supernus Pharmaceuticals is owned by insiders or institutions?

  Currently 3.609% of Supernus Pharmaceuticals shares are held by insiders and 104.632% by institutions.

• How many people work for Supernus Pharmaceuticals?

  Latest data suggests 563 work at Supernus Pharmaceuticals.

• When does the fiscal year end for Supernus Pharmaceuticals?

  Supernus Pharmaceuticals's fiscal year ends in December.

• Where is Supernus Pharmaceuticals based?

  Supernus Pharmaceuticals's address is: 9715 Key West Avenue, Rockville, MD, United States, 20850

• What is Supernus Pharmaceuticals's ISIN number?

  Supernus Pharmaceuticals's international securities identification number is: US8684591089

• What is Supernus Pharmaceuticals's CUSIP number?

  Supernus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 868459108